New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Baywood Launches Ultra Cranberry Extract(TM) to Support Urinary Tract Health

Main Ingredient Proven in Clinical Studies to Help Prevent and Reduce Urinary Tract Infection Symptoms

SCOTTSDALE, Ariz., Jun 14, 2004 /PRNewswire-FirstCall via COMTEX/ -- An extract proven in clinical studies to support urinary tract health called Cran-Max(R) is the main ingredient in Baywood's new Ultra Cranberry Extract(TM). Cran-Max(R) helps prevent and reduce Urinary Tract Infection (UTI) symptoms naturally and promotes a healthy urinary tract. It is the only clinically studied cranberry supplement on the market. Clinical studies have demonstrated that it reduces infections, reduces medical visits and reduces the need for antibiotics.

Cran-Max(R) is concentrated with a potency of 34 to 1, requiring only one dose per day. It is a proprietary mixture of natural plant fibers that form a lignan-cellulose matrix and provides 25% more fiber and more antioxidant activity than cranberry juice. It also contains standardized condensed tannins and fiber, and is the only cranberry supplement that contains the full phytonutrient value of the whole cranberry, not just a portion. In addition, Cran-Max(R) is also the only cranberry supplement which utilizes the BIO-SHIELD system, a patented technology that allows bioactive ingredients to survive stomach acid and pass into the lower Gastrointestinal Tract (GI). This allows the active ingredients of the cranberry to be delivered to the GI for maximum effect.

In the United States, it is estimated that 9.6 million doctor visits annually are attributed to UTIs, with over $1 billion dollars spent per year on treatments. It is the second most common infection in women; 80% of all women will experience a UTI in their lifetime and approximately 20% of women will have a UTI each year. UTIs are the second leading cause of lost work days for women.*

In an outcome study conducted by Dr. Ron Wheeler, 60 women with symptoms of chronic UTIs were recruited from private practice. Each subject filled out a questionnaire (nine questions on a scale from 0-5) before and after taking 500mg of Cran-Max(R) daily. Over 90% of the subjects experienced significant improvement. Another year-long study that was randomized, double-blind, controlled, peer-reviewed and published in The Canadian Journal of Urology in June of 2002 concluded that Cran-Max(R) provided the most effective, convenient, and cost-effective method of prevention for UTI. Other ongoing research is still underway at Veteran's Affairs, Boston Healthcare System and through McMaster University in Hamilton, Ontario, Canada.

Ultra Cranberry Extract(TM) also contains three well-known herbs for supporting urinary tract health: Zea mays (corn silk), Althea officianalis (marshmallow), and Barosma betulina (buchu). These three herbs add components to the formula to make a more complete urinary tract health supplement. Zea mays and Barosma betulina are astringent herbs that also may reduce inflammation, while Althea, a mucilaginous herb, adds a soothing effect.

The product is now available as of June 9th.

About Baywood:

Baywood International, Inc. ("Baywood") (BYWD) is a nutraceutical company specializing in the development, marketing and distribution of its own proprietary brands under the names PURECHOICE(R), SOLUTIONS(R) and Complete La Femme(R). The Company's products are distributed through independent and chain health food stores, pharmacies, grocery stores, and other direct-to-consumer channels both internationally and domestically. Baywood announced May 19, 2004 that it has entered into a letter of intent to acquire Aidan Products, L.L.C. ("Aidan"), specialty nutraceutical company focusing on products that are sold through healthcare practitioner channels. Contact Baywood International, Inc. at 1-888-350-0799 or for more information visit or

*Source: National Institutes of Health

This press release may contain forward-looking statements, made in reliance upon Section 21D of the Exchange Act of 1934, which involve known and unknown risks, uncertainties or other factors that could cause actual results to differ materially from the results, performance, or expectations implied by these forward-looking statements. The Issuer's expectations among other things are dependent upon general economic conditions, continued demand for its products, the availability of raw materials, retention of its key management and operating personnel, as well as other uncontrollable or unknown factors which are more fully disclosed in the Company's Form 10-KSB's and 10-QSB's on file with the United States Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.